TNDM

Over the past six months, Tandem Diabetes Care's stock (TNDM) experienced a 26.09% decrease in the past month, though it showed a 29.19% increase over the last 12 months as of September 23, 2026. The company reported its Q2 2026 earnings on August 6, 2026, with an actual EPS of -0.310 USD, following Q1 2026 earnings of -0.300 USD reported on May 7, 2026. In May 2026, Tandem Diabetes Care reported record first-quarter pump shipments and sales for 2026, with over 29,000 pump shipments worldwide and $247 million in sales, while reaffirming its full-year outlook. U.S. pump shipments exceeded 19,000, and international sales reached $86 million with over 10,000 pumps shipped internationally. In July 2026, the company announced the launch of t:slim X2 insulin pump compatibility with Abbott FreeStyle Libre 3 Plus Sensor in five international markets. In June 2026, Tandem Diabetes Care received CE mark for expanded indications of its automated insulin delivery systems in Europe, approving the t:slim X2 and Tandem Mobi systems with Control-IQ+ AID technology for use by people with type 1 diabetes during pregnancy and adults with type 2 diabetes.